4931
Shinnihonseiyaku Co.,Ltd.
新日本製薬
- Industry
- Chemicals
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Sep 2021
33,899
Sep 2022
36,107
Sep 2023
37,653
Sep 2024
40,043
Sep 2025
41,140
Operating profit(million JPY)
Sep 2021
3,424
Sep 2022
3,522
Sep 2023
3,754
Sep 2024
4,176
Sep 2025
4,782
Operating profit margin(%)
Sep 2021
10.1
Sep 2022
9.75
Sep 2023
9.97
Sep 2024
10.43
Sep 2025
11.62
Profit before tax(million JPY)
Sep 2021
3,401
Sep 2022
3,474
Sep 2023
3,530
Sep 2024
4,110
Sep 2025
4,118
Profit(million JPY)
Sep 2021
2,317
Sep 2022
2,357
Sep 2023
2,394
Sep 2024
2,795
Sep 2025
2,554
Total assets(million JPY)
Sep 2021
23,197
Sep 2022
23,857
Sep 2023
25,501
Sep 2024
27,222
Sep 2025
28,251
Cash and cash equivalents(million JPY)
Sep 2021
13,652
Sep 2022
14,351
Sep 2023
15,518
Sep 2024
16,341
Sep 2025
17,118
Cash flows from operating activities(million JPY)
Sep 2021
2,071
Sep 2022
2,287
Sep 2023
3,468
Sep 2024
2,097
Sep 2025
4,690
Cash flows from investing activities(million JPY)
Sep 2021
-1,359
Sep 2022
-496
Sep 2023
-208
Sep 2024
-382
Sep 2025
-1,794
Cash flows from financing activities(million JPY)
Sep 2021
672
Sep 2022
-1,093
Sep 2023
-2,101
Sep 2024
-902
Sep 2025
-2,098
Return on equity(%)
Sep 2021
14.5
Sep 2022
14
Sep 2023
12.9
Sep 2024
13.6
Sep 2025
11.5
Equity ratio(%)
Sep 2021
68.9
Sep 2022
74.4
Sep 2023
76.5
Sep 2024
79.8
Sep 2025
80.7
Earnings per share(JPY per share)
Sep 2021
107.45
Sep 2022
109.91
Sep 2023
111.37
Sep 2024
129.69
Sep 2025
120.48
Net assets per share(JPY per share)
Sep 2021
747.07
Sep 2022
826.51
Sep 2023
906.72
Sep 2024
1,006.66
Sep 2025
1,078.69
Dividend per share(JPY per share)
Sep 2021
32.5
Sep 2022
33
Sep 2023
33
Sep 2024
45
Sep 2025
52
Payout ratio(%)
Sep 2021
30.25
Sep 2022
30.02
Sep 2023
29.63
Sep 2024
34.7
Sep 2025
43.16
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.